Bayer supports pharmaceutical research in Europe

Bayer supports pharmaceutical research in Europe

10:50 AM, 29th November 2012
Bayers Business News

BERLIN, GERMANY: Bayer HealthCare and Leiden University of The Netherlands will coordinate a newly founded international consortium, dubbed ‘K4DD’ (Kinetics for Drug Discovery), which has been launched to explore a novel concept in modern drug discovery and to tackle a big problem in the development of new drugs. Although successful in early phases of development, many drug candidates fail in clinical studies due to lack of efficacy. The new five-year project will focus on ‘optimizing binding kinetics’ for drug candidates with the goal of improving drug design. The consortium is financially supported with €20 million by Europe’s Innovative Medicines Initiative (IMI).

There is a clear understanding that compound binding characteristics to its molecular target (binding kinetics) is of high importance for eventual clinical drug efficacy. Therefore, drug discovery has also focused on the optimization of these drug-target interactions, mostly with respect to affinity and selectivity. However, despite the efforts in finding high-affinity and selective compounds, attrition rates of candidate drugs are still disappointingly high and almost 90 per cent of clinical drug candidates that enter clinical trials still fail.

“K4DD is an excellent example of a project in which public-private partnerships enable a collaborative research approach to tackle specific drug discovery problems of today and to come up with novel concepts in modern drug discovery. We have assembled a large experienced team of kinetics experts from academic institutions and industrial partners to create a Europe-wide network of complementary capabilities extending far beyond the scope of a traditional ‘one-on-one’ industry-academia collaboration,” said Dr Anke Muller-Fahrnow, Vice President and Head of Lead Discovery Berlin at Bayer HealthCare Global Drug Discovery and Coordinator of the K4DD consortium.

The new concept of ‘target residence time’, the subject of the IMI consortium K4DD represents a novel approach in early drug discovery with the final goal of optimizing drug design. ‘Residence time’ is the time a low-molecular weight (small) molecule remains bound to its target protein and it may be of greater importance for its effect in a patient than its affinity. The consortium was launched to optimize the binding kinetics of each possible drug candidate in the future, ie define its ‘kinotype’, next to its affinity and selectivity.

“The broad support from Europe’s pharma companies and the European Union combined with the expertise within our institute and our partners will enable us to achieve the leverage necessary to tackle this complex project. The joint efforts of this consortium will generate a critical mass to employ drug-target interaction data as a basis for improved drug candidate design and hopefully better patient therapy,” said Prof Ad P IJzerman, Professor, Medicinal Chemistry, Leiden/Amsterdam Centre, Drug Research of Leiden University, The Netherlands.

The K4DD consortium consists of pharma companies, universities, knowledge institutes and smaller companies from all over Europe. The 20 partners in the consortium are European key players in their fields, are at the forefront of bioanalytical techniques and bring the best of computational resources for heavy computer calculations. The goal of this project is that kinetic aspects of drug-target interactions can routinely be studied in robust and accessible assays for all main drug target classes within and outside the consortium. ‘Kinotypic’ knowledge should guide the identification and optimization process of drug candidates in the early phases of drug discovery in the future.

© WOC News





Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Grace completes acquisition of Noblestar Catalysts assets

QINGDAO, CHINA: W R Grace & Co completed acquisition of assets of Noblestar Catalysts Co Ltd, a Qingdao, China-based manufacturer of fluid catalyt ...

Read more
Presence of hazardous chemicals in mobile phones, finds survey

MICHIGAN, US: sampled 36 different mobile phones that had been released in the last 5 years. The phones were completely disassembled; ...

Read more
SunEdison closes $314 million funding for South Africa solar projects

JOHANNESBURG, SOUTH AFRICA/BELMONT, US: SunEdison, subsidiary of MEMC Electronic Materials, in partnership with Chint Solar, the Public Investment Cor ...

Read more
Foster Wheeler acquires Canadian EPC management firm

ZUG, SWITZERLAND: Foster Wheeler AG has acquired Three Streams Engineering Ltd, a privately held engineering company located in Calgary, Canada. Three ...

Read more
Sasol’s gas engine power plant begins electricity production

JOHANNESBURG, SOUTH AFRICA: Sasol’s R1.9 billion gas engine power plant in Sasolburg has gone live and began producing electricity, for the firs ...

Read more
Helm to expand Jushi’s thermoplastic glass fibre business in EU market

HAMBURG, GERMANY/TONGXIANG, CHINA/AACHEN, GERMANY: Helm AG has appointed Michael Effing (AMAC) to advise, promote and further develop the introduction ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X